ProPhase Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics Technologies - Seite 2

The Company plans to establish its presence in each of the countries with Nebula-branded genomic labs, funded by its potential strategic partners, with a particular focus on the UAE, where the government has made substantial investments in genomics. This initiative is aimed at establishing localized laboratories that will keep the genomic samples within the country while expanding Nebula's library of data. Countries are often hesitant or prohibited from sending their samples across borders. The Company is also exploring offering a 'white label' version of its whole genome sequencing kits, branded by the local partner in exchange for a royalty and access to the data. This move would further enhance Nebula's global reach to the 400 million inhabitants of the MENA region.

By harnessing the potential of genomics, AI, and advanced diagnostics, ProPhase aspires to profoundly impact patient outcomes and advance public health, aligning with the UAE government's vision.

Alongside its genomics approach, ProPhase Labs is in active discussions to partner and introduce its BE-SMART Esophageal Cancer Test to the MENA region.

“We believe BE-SMART has the potential to be the gold standard of esophageal cancer testing, setting the bar for highly accurate predictive testing in this vital space. The UAE has witnessed an alarming rise in esophageal cancer cases, with an estimated 1,200 new cases reported and 600 related deaths in 2022 alone. Esophageal cancer ranks as the 10th most prevalent cancer in the UAE and the 8th leading cause of cancer-related mortality. Acknowledging this urgent healthcare concern, the UAE government has recently announced the launch of a national screening program that targets individuals at high risk of developing esophageal cancer, such as those with Barrett's Esophagus (BE) or dysplasia. The program employs a range of screening tests like endoscopy and biopsy. By detecting and addressing the disease at its early stages, the program aims to significantly improve patient outcomes and enhance public health in the UAE. The market currently lacks a test that can predict BE progression to esophageal adeno carcinoma (EAC). BE-SMART’s high degree of sensitivity (true positive predictive ability) and specificity (true negative predictive ability) promises to change that. The BE-SMART test can potentially save many lives. At the same time, low risk patients won’t have to walk around wondering if they are going to develop EAC and be subjected to yearly endoscopies. Furthermore, this test could potentially save insurance companies billions of dollars in unnecessary endoscopy procedures.”